Coya Therapeutics Inc
NASDAQ:COYA
Net Margin
Coya Therapeutics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
C
|
Coya Therapeutics Inc
NASDAQ:COYA
|
92m USD |
-4 803%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
393B USD |
6%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
153.6B USD |
19%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
141.7B USD |
22%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
98.2B USD |
32%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
96.1B AUD |
19%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
63B USD |
31%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
59.4B USD |
-13%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Coya Therapeutics Inc
Glance View
Coya Therapeutics, Inc. is a clinical-stage biotechnology company engaged in developing approaches utilizing Treg modifying therapeutics to target systemic and neuro inflammation. The company is headquartered in Houston, Texas. The company went IPO on 2022-12-29. The firm is focused on developing new therapies to enhance the function of regulatory T cells (Tregs). The company is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases. The company has a diversified product candidate pipeline that includes both ex vivo (outside the body) and in vivo (inside the body) therapeutic approaches intended to restore the suppressive and immunomodulatory functions of Tregs. Its 300 Series product candidates include COYA 301 and COYA 302, its 200 Series product candidates include COYA 201 and COYA 206, and its 100 Series product candidate is COYA 101. Its COYA 301 is a biologic for subcutaneous administration. Its COYA 302 is a combination of two molecules for subcutaneous and/or intravenous administration. Its COYA 201 product candidate utilizes its Treg-derived exosome therapeutic modality. Its COYA 101 is its autologous regulatory T-cell product candidate.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Coya Therapeutics Inc's most recent financial statements, the company has Net Margin of -4 802.6%.
You don't have any saved screeners yet